Patents by Inventor Simone Filosto
Simone Filosto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12343394Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: June 8, 2018Date of Patent: July 1, 2025Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Patent number: 12161717Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: June 8, 2018Date of Patent: December 10, 2024Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Patent number: 12162949Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: January 18, 2022Date of Patent: December 10, 2024Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
-
Publication number: 20240309428Abstract: The disclosure relates to methods of prognosis and therapy, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non-T cells, TCR-based therapies, and CAR-based therapies).Type: ApplicationFiled: March 14, 2024Publication date: September 19, 2024Inventors: Simone Filosto, Gayatri R. Tiwari, Justin Szu-Ting Chou
-
Publication number: 20240158869Abstract: The disclosure relates to methods for treating a malignancy in a subject with a cell therapy, methods of predicting a likelihood of response to the cell therapy product in the subject, and methods of predicting a likelihood of CAR T-cell exhaustion in the cell therapy product.Type: ApplicationFiled: October 27, 2023Publication date: May 16, 2024Inventors: Simone Filosto, Michael D. Mattie, Saad Kenderian, Carli M. Stewart
-
Publication number: 20240092928Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: September 1, 2023Publication date: March 21, 2024Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Patent number: 11780930Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: June 8, 2018Date of Patent: October 10, 2023Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Publication number: 20230103584Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: June 8, 2018Publication date: April 6, 2023Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Publication number: 20230089373Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: November 30, 2022Publication date: March 23, 2023Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
-
Patent number: 11542338Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: August 16, 2018Date of Patent: January 3, 2023Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
-
Publication number: 20220135697Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: January 18, 2022Publication date: May 5, 2022Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
-
Patent number: 11236173Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: August 16, 2018Date of Patent: February 1, 2022Inventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
-
Publication number: 20210277138Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: June 8, 2018Publication date: September 9, 2021Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenchea Corzo, Hemanta Baruah, Bianka Prinz
-
Publication number: 20200362050Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: August 16, 2018Publication date: November 19, 2020Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
-
Publication number: 20200362049Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: August 16, 2018Publication date: November 19, 2020Inventors: Anne GOUBIER, Josephine SALIMU, Kevin MOULDER, Beatriz GOYENECHEA CORZO, Simone FILOSTO, Pascal MERCHIERS, Nina EISSLER, Hemanta BARUAH, Bianka PRINZ
-
Publication number: 20200190209Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: June 8, 2018Publication date: June 18, 2020Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
